There are a variety of options, both pharmacological and non-pharmacological, available for the treatment of atopic dermatitis. The recent approval of PROTOPIC® as a twice-weekly maintenance therapy to control flares and to prolong flare-free periods represents an important step forward in the way in which atopic dermatitis is managed. The large volume of clinical trial data supporting the efficacy and tolerability of PROTOPIC®, used either as a reactive therapy to control flares, or as a preventative measure to stop flares recurring, demonstrates that this is a valuable treatment option for controlling atopic dermatitis.
© February 2010 Astellas Pharma Europe LTD.
Disclaimer:
The Atopic Dermatitis Knowledge centre contained within www.epgonline.org and available at www.atopicdermatitisinfo.org is intended to be for educational use only and not designed to provide medical advice or professional services.